Patents Assigned to Glycotope GmbH
-
Publication number: 20210221910Abstract: The present disclosure pertains to novel antibodies directed against the cancer antigen MUC1. In particular, an antibody with improved antigen binding was obtained by deleting a glycosylation site in the CDR-H2 of a known anti-MUC1 antibody.Type: ApplicationFiled: May 17, 2019Publication date: July 22, 2021Applicant: GLYCOTOPE GMBHInventors: Johanna GELLERT, Anke FLECHNER, Doreen WEIGELT, Antje DANIELCZYK
-
Patent number: 10752914Abstract: Some embodiments of the methods and compositions provided herein relate to the preparation surfactant protein-D (SP-D). Some embodiments include the expression of human SP-D in certain cell lines, and the purification of human SP-D from such cell lines. Some embodiments include the preparation of certain oligomeric forms of human SP-D.Type: GrantFiled: September 4, 2018Date of Patent: August 25, 2020Assignees: Airway Therapeutics, Inc., Glycotope GmbHInventors: Jan Susan Rosenbaum, Frederick Gyapon Quast, Matthias Kaup, Lars Stöckl
-
Publication number: 20200087410Abstract: The present invention pertains to humanized anti-CD40 antibodies having antigen binding properties similar to those of the parent chimeric anti-CD40 antibody and increased Fc? receptor binding affinities. In particular, the present invention is directed to humanized anti-CD40 antibodies which are useful in the treatment of cancer, infections and immunodeficiencies.Type: ApplicationFiled: March 27, 2018Publication date: March 19, 2020Applicant: Glycotope GmbHInventors: Steffen GOLETZ, Antje DANIELCZYK, Anja LOFFLER, Doreen WEIGELT, Patrick KEHLER
-
Patent number: 10280230Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.Type: GrantFiled: May 4, 2015Date of Patent: May 7, 2019Assignee: Glycotope GmbHInventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Loeffler, Lars Stoeckl
-
Patent number: 10184135Abstract: The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.Type: GrantFiled: March 30, 2016Date of Patent: January 22, 2019Assignee: Glycotope GmbHInventors: Steffen Goletz, Doreen Jahn, Antje Danielczyk
-
Publication number: 20180094279Abstract: The present invention pertains to the field of recombinant protein production. Novel expression cassettes comprising elements of the human globin gene clusters are provided which show enhanced expression rates of proteins or polypeptides of interest.Type: ApplicationFiled: March 30, 2016Publication date: April 5, 2018Applicant: Glycotope GmbHInventors: Steffen GOLETZ, Doreen JAHN, Antje DANIELCZYK
-
Patent number: 9845361Abstract: The invention relates to recognition molecules directed towards tumors, and it also relates to pharmaceutical compositions comprising said recognition molecules, methods for the production of said recognition molecules, and to the use of said recognition molecules in the diagnosis and therapy of tumor diseases.Type: GrantFiled: June 26, 2014Date of Patent: December 19, 2017Assignee: GLYCOTOPE GmbHInventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
-
Patent number: 9700610Abstract: The present invention pertains to microorganisms of the species Bacteroides xylanisolvens expressing a core-1 antigen on their surface. These microorganisms are in particular useful for the prophylaxis and treatment of core-1 positive diseases and are particularly characterized by a stable, homogenous high core-1 expression. Also provided are pharmaceutical compositions which comprise respective core-1 positive microorganisms or fractions thereof.Type: GrantFiled: August 22, 2012Date of Patent: July 11, 2017Assignee: Glycotope GmbHInventors: Steffen Goletz, Philippe Ulsemer, Kawe Toutounian
-
Patent number: 9527899Abstract: The present invention pertains to improved FSH preparations which are capable of stimulating sex steroid release at much lower concentration than the commonly used urinary FSH or recombinant FSH obtained from CHO cells and which act independent of cAMP signaling These improved FSH preparations can be used in infertility treatment.Type: GrantFiled: August 4, 2011Date of Patent: December 27, 2016Assignee: Glycotope GmbHInventors: Steffen Goletz, Lars Stöckl
-
Patent number: 9494587Abstract: The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive carcinomas. The invention relates to coreotics and a method of producing the same and to a method of prevention and treatment of core-1 positive disorders using the same. The invention relates to microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates.Type: GrantFiled: November 12, 2007Date of Patent: November 15, 2016Assignee: Glycotope GmbHInventors: Steffen Goletz, Phillippe Ulsemer, Anja Löffler
-
Patent number: 9487567Abstract: The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to generate an immune response in humans. The invention further relates to methods for producing medicaments and diagnostic agents. Also disclosed is the use of the MUC1 molecules, cells or cell lysates obtained by means of the methods according to the invention for producing a medicament used for treating or preventing tumors. Further disclosed is a purified MUC1 molecule that can be obtained by means of the methods according to the invention and has an immunostimulating effect on humans. The invention additionally relates to the use of a MUC1 antibody for the production of a medicament used for treating or preventing tumors.Type: GrantFiled: January 6, 2014Date of Patent: November 8, 2016Assignee: GLYCOTOPE GMBHInventors: Steffen Goletz, Uwe Karsten
-
Patent number: 9359439Abstract: The present invention pertains to a method for controlling the circulation half-life of antibodies by adjusting the amount of sialic acid in the carbohydrates attached to the Fab part of the antibodies. Furthermore, the present invention provides antibodies having an increased circulation half-life.Type: GrantFiled: August 10, 2011Date of Patent: June 7, 2016Assignee: Glycotope GmbHInventors: Steffen Goletz, Antje Danielczyk, Lars Stoeckl
-
Patent number: 9359427Abstract: The present invention pertains to a method for culturing a suspension of immortalized human blood cells, preferably cells of myeloid leukaemia origin or cells derived therefrom, wherein said method provides a high productivity, a high cell viability and growth rate and a high batch-to-batch consistency, and can be scaled up without altering these parameters.Type: GrantFiled: December 21, 2011Date of Patent: June 7, 2016Assignee: Glycotope GmbHInventor: Rainer Stahn
-
Patent number: 9217038Abstract: The present invention pertains to anti-mucin antibodies having improved antigen binding and/or recognition properties as well as a method for improving the antigen binding and/or recognition of an anti-mucin antibody. In particular, the present invention is directed to anti-MUC1 antibodies which are useful in the treatment of cancer.Type: GrantFiled: July 30, 2010Date of Patent: December 22, 2015Assignee: GLYCOTOPE GMBHInventors: Steffen Goletz, Antje Danielczyk, Renate Stahn, Uwe Karsten
-
Publication number: 20150166664Abstract: The present invention pertains to the field of cancer therapy using anti-cancer antibodies. The medical use of anti-HER2 antibodies having improved glycosylation characteristics, in particular a reduced fucosylation, is provided which show enhanced efficacy.Type: ApplicationFiled: July 18, 2013Publication date: June 18, 2015Applicant: GLYCOTOPE GMBHInventors: Steffen Goletz, Antje Danielczyk
-
Patent number: 9051356Abstract: The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.Type: GrantFiled: September 10, 2007Date of Patent: June 9, 2015Assignee: Glycotope GmbHInventors: Steffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Löffler, Lars Stöckl
-
Patent number: 9051370Abstract: The present invention pertains to humanized anti-EGFR antibodies having antigen binding properties similar to those of the murine or chimeric anti-EGFR antibody from which they are derived. In particular, the present invention is directed to humanized anti-EGFR antibodies which are useful in the treatment of cancer.Type: GrantFiled: August 10, 2011Date of Patent: June 9, 2015Assignee: Glycotope GmbHInventors: Steffen Goletz, Antje Danielczyk
-
Patent number: 9029143Abstract: The invention is related to the production and use of CD124+ and CD116+ cell lines for the production of effective dendritic cells (DC) using stimulatory molecules, their use in the production of allogenic or semi-allogenic immunotherapeutic agents and the use thereof in the treatment or prophylaxis of immune diseases. Furthermore, the invention is related to the use of CD124+ and CD116+ tumor cell lines, preferably also being CD34+, as model and test systems for testing the DC biology and for testing substances having an impact on the immune system and on the conditioning thereof.Type: GrantFiled: July 19, 2012Date of Patent: May 12, 2015Assignee: Glycotope GmbHInventors: Steffen Goletz, Rik J. Scheper, Alan Masterson, Herbert M. Pinedo
-
Publication number: 20150118354Abstract: The present invention pertains to food products comprising microorganisms of the species Bacteroides xylanisolvens, in particular fermented food and probiotic food. These microorganisms are particularly characterized as having a very low pathogenicity and a high safety for human consumption. Furthermore, methods for producing said food products, in particular by fermentation, as well as suitable bacterial strains Bacteroides xylanisolvens of are provided.Type: ApplicationFiled: August 22, 2012Publication date: April 30, 2015Applicant: GLYCOTOPE GMBHInventors: Steffen Goletz, Philippe Ulsemer, Kawe Toutounian
-
Publication number: 20150010495Abstract: The present invention relates to a method for producing or identifying a MUC1 molecule which is able to generate an immune response in humans. The invention also relates to a method for producing or identifying a cell, cell lines or cell lysates containing a MUC1 molecule that is able to generate an immune response in humans. The invention further relates to methods for producing medicaments and diagnostic agents. Also disclosed is the use of the MUC1 molecules, cells or cell lysates obtained by means of the methods according to the invention for producing a medicament used for treating or preventing tumours. Further disclosed is a purified MUC1 molecule that can be obtained by means of the methods according to the invention and has an immunostimulating effect on humans. The invention additionally relates to the use of a MUC1 antibody for the production of a medicament used for treating or preventing tumours.Type: ApplicationFiled: January 6, 2014Publication date: January 8, 2015Applicant: GLYCOTOPE GMBHInventors: Steffen Goletz, Uwe Karsten